News

InTB Winners Announced!

Inaugural entrants showcase successful new approaches

Thank you to all who submitted entries to the first InnovateTB contest. We are delighted to be able to help promote them as an ongoing effort of the InnovateTB Library.

At the request of our stakeholders, we divided the winners into three categories: Overall Winner, Advocacy Winner (both selected from the popular vote getters by the expert panel), and Fan Favorite (most popular vote getter). We are proud to announce the 2012 InTB Award winners as follows:

Overall Winner

Advocacy Winner

Fan Favorite

ACTION: New technology saves lives

Delft Youth Theatre

The Electronic TB Register

Runner Up

Runner Up

Runner Up

A New Hope for Tuberculosis (MM4TB)

Stop TB’s Challenge Facility for Civil Society

Signature Mapping TBDx

Winners were determined by a combination of popular votes and review by our expert panel members. We would like to thank the panel for their time and guidance:

  • Veronique Dartois — Assistant Professor, Public Health Research Institute, UMDNJ
  • Lucica Ditiu — Executive Secretary, Stop TB Partnership
  • Ken Duncan — Deputy Director, Bill and Melinda Gates Foundation
  • Shobha Shukla — Editor and Director Diabetes Media Initiative, Citizen New Service

Beyond the scope of this contest, InTB aims to catalog and promote groundbreaking work in TB diagnosis, control, and treatment. We invite you to continue to submit innovations to our ongoing library — videos, photos or written accounts for TB innovations you have been involved in.

We look forward to seeing more TB Innovations!

More News
3 Feb 2021
Last week, the World Health Organization (WHO) held a consultation to discuss the definition of extensively drug resistant (XDR) tuberculosis. The meeting was held to discuss novel treatment regimens and diagnostics for drug-resistant TB and determine its impact on the definition of XDR-TB. The...
10 Dec 2020
The Stop TB Partnership Working Group on New TB Vaccines (WGNV), Working Group on New TB Drugs (WGND), and New Diagnostics Working Group (NDWG) are developing an online course specifically designed for advocates and affected communities to provide a base of knowledge in TB research and to generate...
22 Oct 2020
On Thursday, October 21st, 2020, the U.S. Centers for Disease Control and Prevention's (CDC) TB Trials Consortium (TBTC) announced results from their Phase 3, open-label trial: Study 31/A5349. The clinical trial identified a 4-month drug regimen composed of high-dose rifapentine, moxyifloxacin,...